Vaccines Beyond the Pandemic: A Quietly Reinvigorated Category

The Fall That Obscured the Second Act

Vaccine investing fell out of fashion faster than almost any other healthcare category once the acute phase of the COVID-19 pandemic passed. Moderna’s market capitalization, which peaked near half a trillion dollars during the pandemic, gave back the overwhelming majority of that value as investors correctly recognized that a single infectious-disease emergency does not translate into a durable, repeatable commercial franchise — a company built almost entirely around a single vaccine for a single, thankfully transient emergency was never going to sustain a pandemic-era valuation once that emergency receded, and the market’s correction was, on its own terms, a reasonable repricing rather than an overreaction.

What that retreat obscured, and what deserves separate attention now, is that the mRNA platform built for COVID has quietly found a second application that looks considerably more interesting from a long-term value-creation standpoint: personalized cancer vaccines, built not to prevent a disease but to treat one that a patient already has. That is a genuinely different commercial proposition from a pandemic vaccine — an oncology therapeutic priced and reimbursed the way other cancer treatments are, sold into an ongoing, chronic disease-management relationship rather than a one-time emergency public-health procurement contract.

How a Personalized Cancer Vaccine Actually Works

The clearest evidence is the Moderna-Merck collaboration around intismeran autogene, previously known by the less pronounceable designation mRNA-4157/V940. The mechanism is genuinely novel and worth walking through in some detail, because it is meaningfully different from how the mRNA vaccine platform was used during the pandemic. A COVID vaccine encodes a single, fixed viral protein, identical for every patient who receives it. A personalized neoantigen vaccine does the opposite: it sequences an individual patient’s resected tumor, identifies the specific mutations — neoantigens — unique to that patient’s cancer, and manufactures a bespoke mRNA vaccine encoding those exact targets, administered alongside Merck’s checkpoint inhibitor Keytruda. No two patients receive an identical product; the vaccine is, by design, a unique manufactured good for every single course of treatment.

That individualization is precisely what makes the mechanism potentially so powerful clinically — it trains the immune system to recognize exactly the mutations present in that patient’s specific tumor, rather than relying on a shared antigen that may or may not be present or accessible in every patient’s cancer. It is also precisely what makes the manufacturing problem so much harder than a conventional vaccine, a tension explored further below.

The Data Behind the Enthusiasm

Five-year follow-up data from the Phase 2b KEYNOTE-942 trial, released in January 2026, showed the combination sustaining a 49 percent reduction in the risk of recurrence or death in resected high-risk melanoma compared to Keytruda alone — essentially unchanged from the three-year readout, evidence that the immune-priming effect is durable rather than a short-lived bump. That durability point is clinically important in a specific way: a therapy that produces a strong effect at three years but fades by five would suggest the vaccine is delaying recurrence rather than genuinely altering the disease’s underlying trajectory. Data holding essentially flat between the three- and five-year readouts is a considerably stronger signal that something more fundamental is happening to how the immune system is surveilling for recurrence.

Five-year overall survival ran 92.2 percent in the combination arm versus 71.3 percent for Keytruda alone — roughly a twenty-one-percentage-point absolute difference in survival, a magnitude of benefit that is genuinely unusual in oncology, where incremental improvements of a few percentage points are far more typical of what a positive Phase 3 trial actually delivers.

Scaling Beyond Melanoma

The companies are not treating this as a melanoma-specific result. A global Phase 3 program, targeting more than a thousand patients across the US, Europe, Australia, and Asia, is now underway in adjuvant melanoma, with additional Phase 2 and 3 studies running in parallel across non-small cell lung cancer, bladder cancer, and renal cell carcinoma — eight separate trials in total as of early 2026, a genuinely broad clinical development program for a modality this novel, reflecting real confidence from both companies that the mechanism generalizes beyond the original melanoma indication where it was first validated.

Separately, a personalized mRNA vaccine developed by Memorial Sloan Kettering Cancer Center with BioNTech has shown vaccine-induced immune responses persisting for close to four years in pancreatic ductal adenocarcinoma patients, one of oncology’s most stubbornly difficult cancers to treat at all, let alone durably — a disease where five-year survival rates have historically remained in the single digits despite decades of drug-development effort, which makes even an early, immunologically-focused signal in this specific cancer type genuinely notable to the field.

The Manufacturing Stress Test

What makes this a genuinely distinct thesis from the broader oncology pipeline discussed elsewhere in this issue is the manufacturing model it requires, which is unlike almost anything else in pharmaceutical production. A personalized neoantigen vaccine cannot be made in advance and stockpiled — it has to be manufactured individually, from a specific patient’s tumor sequence, within a clinically usable window, commonly cited at roughly six to eight weeks from biopsy to dose. Miss that window, in a disease as aggressive as high-risk melanoma or lung cancer, and the adjuvant treatment opportunity can simply pass the patient by while manufacturing is still underway.

Running that process at the scale a global Phase 3 trial requires, across multiple continents and regulatory jurisdictions simultaneously, is as much a stress test of Moderna’s manufacturing and logistics infrastructure as it is a test of the clinical hypothesis. Sites span the US, Europe, Australia, and Asia specifically because regulators in each of those jurisdictions want to see indigenous manufacturing and delivery performance data before committing to reimbursement — which means Moderna has to prove it can sequence a tumor, synthesize a bespoke mRNA product, and deliver a dose within that six-to-eight-week window reliably, on essentially every populated continent simultaneously, not merely at a single flagship facility. If the platform proves durable at that scale, it becomes a genuinely new template for how personalized medicine reaches industrial throughput rather than remaining a boutique, single-institution capability — and if it does not, the resulting operational data will be just as informative for the rest of the industry’s personalized-medicine ambitions.

Beyond Oncology: The Infrastructure Lives On

Beyond oncology, the broader mRNA and adjuvant-technology platforms built out during the pandemic have not disappeared — they have redirected toward a longer list of previously under-addressed infectious targets, from next-generation respiratory syncytial virus vaccines to combination respiratory formulations aimed at reducing the number of separate seasonal injections a patient needs. None of that is as commercially dramatic as a cancer vaccine story, but it represents genuine, durable public-health value built on infrastructure that would otherwise have sat idle once pandemic-era demand receded, and it is a reminder that platform infrastructure, once built at genuine scale, tends to find productive uses well beyond the emergency that originally justified building it.

A Specific Thesis, Not a Blanket One

For a healthcare-focused fund, the read here is specific rather than a blanket “vaccines are back” thesis, which would overstate the case. The infectious-disease vaccine market has genuinely normalized to something closer to its pre-pandemic scale and growth rate, and companies whose business model depended on sustained pandemic-level demand have largely been correctly repriced downward.

The therapeutic cancer vaccine category is a different animal entirely — earlier stage, higher risk, but backed by genuinely durable five-year clinical data and a manufacturing platform with real industrial ambitions behind it. It sits at the intersection of two of this issue’s other themes, oncology’s combination-therapy shift and the broader AI-and-genomics-driven personalization trend, and it is where we are directing the vaccine-category diligence time that, three years ago, would have gone almost entirely toward infectious disease.

What the Correction Actually Taught

The lesson of the post-pandemic vaccine correction is not that vaccines stopped mattering. It is that the platform built for one emergency found a more durable second calling nobody had fully underwritten at the time — which is, more often than the industry likes to admit, how the most interesting long-term theses in healthcare venture actually get built: not by predicting the second act in advance, but by staying attentive enough to a platform’s underlying capability to notice it when the data starts arriving.